Cite

    Taylor, P. C., Takeuchi, T., Burmester, G. R., Durez, P., Smolen, J. S., Deberdt, W., Issa, M., Terres, J. R., Bello, N., & Winthrop, K. L. (2022). safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Annals of the rheumatic diseases, 81(3), 335–343. http://access.bl.uk/ark:/81055/vdc_100151273751.0x000056